Functional, cross-linked nanostructures for tandem optical imaging and therapy

US9295650B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9295650-B2
Application numberUS-201113697149-A
CountryUS
Kind codeB2
Filing dateNov 17, 2011
Priority dateMay 14, 2010
Publication dateMar 29, 2016
Grant dateMar 29, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that include one or more photoactive moieties. The present invention further includes imaging and therapeutic methods using one or more optical agents of the present invention including optically functional shell cross-linked micelles having an associated therapeutic agent.

First claim

Opening claim text (preview).

What is claimed is: 1. An optical agent comprising: an optical agent comprising cross linked block copolymers, wherein each of the block copolymers comprises a hydrophilic block and a hydrophobic block; and linking groups covalently cross linking at least a portion of the hydrophilic blocks of the block copolymers, wherein at least a portion of the linking groups comprise one or more photoactive moieties; and a therapeutic agent that is a cytotoxic moiety, a DNA intercalating anthracycline, a chemotherapy agent, an alkylating agent, a DNA intercalator, a microtubule-targeting molecule, a folate antagonist, a nucleoside antimetabolite, an antineoplastic agent, a platinum complex, a Taxol, a Type I photodvnamic compound or a Type II photodvnamic compound; wherein the optical agent forms a supramolecular structure in aqueous solution, the supramolecular structure having an interior hydrophobic core and a covalently cross linked hydrophilic shell, wherein the interior hydrophobic core comprises the hydrophobic blocks of the block copolymers, and the covalently cross linked hydrophilic shell comprises the hydrophilic blocks of the block copolymers, wherein the therapeutic agent is at least partially encapsulated by the supramolecular structure and the therapeutic agent is non-covalently associated with the hydrophobic core, and wherein the optical agent is a shell-cross linked rod-shaped nanostructure. 2. The optical agent of claim 1 wherein the one or more photoactive moieties comprise one or more fluorophores capable of excitation upon absorption of electromagnetic radiation having wavelengths selected over a range of 400 nanometers to 1300 nanometers, and capable of emission of electromagnetic radiation having wavelengths selected over a range of 400 nanometers to 1300 nanometers. 3. The optical agent of claim 1 wherein the one or more photoactive moieties comprises a Type I or Type II phototherapeutic agent. 4. The optical agent of claim 1 wherein the one or more photoactive moieties comprises a pyrazine. 5. The optical agent of claim 1 wherein the mole ratio of the linking groups to monomers of the hydrophilic blocks is selected over a range of 1:100 to 99:100. 6. The optical agent of claim 1 wherein the block copolymers are diblock copolymers, triblock copolymers, polyblock copolymers or graft colymers. 7. The optical agent of claim 1 wherein the hydrophobic block is a poly(p-hydroxystyrene) polymer block; a polystyrene polymer block; a poly(p-hydroxystyrene) polymer block; a polyacrylate polymer block; a poly(propylene glycol) polymer block; a poly(ester) polymer block; a polylactic acid polymer block; a poly(tert-butylacrylate) polymer block; a poly(N-acryloxysuccinimide) polymer block; a poly(methyl acrylate) polymer block; a poly(ε-caprolactone) polymer block; a poly(glycolic acid) polymer block; a polylactide polymer block; or a polyglycolide polymer block; or a copolymer thereof. 8. The optical agent of claim 1 wherein the hydrophilic block is a poly(acrylic acid) polymer block; a poly(ethylene glycol) polymer block; a poly(acetoxystyrene) polymer block; or a copolymer thereof. 9. The optical agent of claim 1 wherein a hydrophilic block is a poly(acrylic acid) polymer block, a hydrophobic block is a poly(p-hydroxystyrene) block and the linking groups are bound to monomers of the poly(acrylic acid) polymer block by amide bonds. 10. The optical agent of claim 1 wherein at least a portion of the hydrophilic blocks of the block copolymers and linking groups have the formula: wherein each of R 1 -R 6 is independently selected from the group consisting of —R, —COOR,—COR, —CON(R) 2 , —OCON(R) 2 , —N(R) 2 , —SR, —SO 2 R, —SOR, —OCOOR, —SO 2 N(R) 2 , and —OR; each R is independently selected from the group consisting of a hydrogen, C 1 -C 20 alkyl, C 5 -C 20 aryl, C 1 -C 20 carbonyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, C 5 -C 20 alkylaryl, C 1 -C 20 alkoxy, halo, amine, amide, hydroxyl, carboxyl, cyano, a nitrile group, an azide group, a nitro group, an acyl group, a thiol group or a natural or non-natural amino acid or fragment thereof; each of Z 1 and Z 2 is independently wherein one or more CH 2 groups may be replaced by NH, O, S, a carbonyl (C═O), or a sulfonyl (S═O or O═S═O); two adjacent CH 2 groups may be replaced by —CH═CH— or —C═C—; and wherein each e is independently is selected from the range of 0 to 10; and each of a and b is independently 0 or 1; or wherein at least a portion of the hydrophilic blocks of the block copolymers and linking groups have the formula: wherein each of R 1 -R 14 is independently selected from the group consisting of —R, —COOR, —COR, —CON(R) 2 , —OCON(R) 2 , —N(R) 2 , —SR, —SO 2 R, —SOR, —OCOOR, —SO 2 N(R) 2 , and —OR; each R is independently selected from the group consisting of a hydrogen, C 1 -C 20 alykl, C 5 -C 20 aryl, C 1 -C 20 carbonyl, C 2 -C 20 alkenyl, C 5 -C 20 alkynyl, C 5 -C 20 alkylaryl, C 1 -C 20 alkoxy, halo, amine, amide, hydroxyl, carboxyl, cyano, a nitrile group, an azide group, a nitro group, an acyl group, a thiol group or a natural or non-natural amino acid or fragment thereof; each of u and v is independently selected from the range of 0 to 10; each of Z 3 -Z 6 is independently wherein one or more CH 2 groups may be replaced by NH, O, S, a carbonyl (C═O), or a sulfonyl (S═O or O═S═O); two adjacent CH 2 groups may be replaced by —CH═CH— or —C═C—; and wherein each e is independently is selected from the range of 0 to 10. 11. The optical agent of claim 10 wherein at least one of R 8 , R 11 , R 13 , and R 14 is: 12. The optical agent of claim 1 wherein at least a portion of the hydrophilic blocks of the block copolymers and linking groups have the formula: wherein each p is selected from the range of 20 to 250, wherein independently for each value of p, n is independently a number from 1 to 0 and m is independently a number from 1 to 0; wherein each of R 1 -R 6 is independently selected from the group consisting of —R, —COOR, —COR, —CON(R) 2 , —OCON(R) 2 , —N(R) 2 , —SR, —SO 2 R, —SOR, —OCOOR, —SO 2 N(R) 2 , and —OR; each R is independently selected from the group consisting of a hydrogen, C 1 -C 20 alkyl, C 5 -C 20 aryl, C 1 -C 20 carbonyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, C 5 -C 20 alkylaryl, C 1 -C 20 alkoxy, halo, amine, amide, hydroxyl, carboxyl, cyano, a nitrile group, an azide group, a nitro group, an acyl group, a thiol group or a natural or non-natural amino acid or fragment thereof; each of R 17 and R 18 is independently selected from the group consisting of —R, —COOR, —COR, —CON(R) 2 , —OCON(R) 2 , —N(R) 2 , —SR, —SO 2 R, —SOR, —OCOOR, —SO 2 N(R) 2 , and —OR; each R is independently selected from the group consisting of a hydrogen, C 1 -C 20 alkyl, C 5 -C 20 aryl, C 1 -C 20 carbonyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, C 5 -C 20 alkylaryl, C 1 -C 20 alkoxy, halo, amine, amide, hydroxyl, carboxyl, cyano, a nitrile group, an azide group, a nitro group, an acyl group, a thiol group, a natural or non-natural amino acid or fragme

Assignees

Inventors

Classifications

  • Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle · CPC title

  • Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title

  • Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes · CPC title

  • having four-membered rings, e.g. taxol · CPC title

  • Processes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9295650B2 cover?
The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that …
Who is the assignee on this patent?
Neumann William L, Dorshow Richard B, Freskos John N, and 7 more
What technology area does this patent fall under?
Primary CPC classification A61K41/0057. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).